contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


demant-as-gennemforelse-af-kapitalnedsaettelse-2

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Demant operates in the medical technology sector. The company specializes in the development of hearing aids and hearing loops. The company operates on a global level where the products are sold under various brands. The products are available through the company's distributors and sales channels. In addition to its main business, the company conducts research in diagnostics for measuring hearing quality. The company was originally founded in 1904 and has its headquarters in Smörum.

Demant

8.4.2026 11:02:53 CEST | Demant A/S | Antal stemmerettigheder og kapitalSelskabsmeddelelse nr. 2026-07 8. april 2026Gennemførelse af kapitalnedsættelse i Demant A/S Som oplyst i selskabsmeddelelse...

<p class="prs-announcement__byline">8.4.2026 11:02:53 CEST | Demant A/S |    Antal stemmerettigheder og kapital</p><table class="prs-table"><tbody><tr><td><p><strong>Selskabsmeddelelse</strong><strong> </strong><strong>nr. 2026-07</strong></p></td><td><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8. april 2026</strong></p></td></tr></tbody></table><p><strong>Gennemførelse af kapitalnedsættelse i Demant A/S</strong></p><p>&nbsp;</p><p>Som oplyst i selskabsmeddelelse nr. 2026-05 blev det på Demant A/S’ ordinære generalforsamling den 5. marts 2026 besluttet at nedsætte selskabets aktiekapital med nominelt DKK 408.274,40 fordelt på 2.041.372 stk. aktier a DKK 0,20 svarende til selskabets beholdning af egne aktier pr. 3. februar 2026 fraregnet aktier til dækning af ledende medarbejderes og direktionens aktiebaserede fastholdelsesprogrammer.</p><p>&nbsp;</p><p>Offentliggørelse af kapitalnedsættelsen har fundet sted i Erhvervsstyrelsens it-system den 6. marts 2026. Proklamafristen er udløbet uden indsigelser. Kapitalnedsættelsen er derfor anmeldt endeligt til Erhvervsstyrelsen. Efter kapitalnedsættelsen udgør aktiekapitalen i Demant A/S nominelt DKK 42.350.658,20.</p><p>&nbsp;</p><p>I henhold til § 32 i lov om kapitalmarkeder oplyses det hermed, at selskabets samlede aktiekapital og samlede antal stemmerettigheder er opgjort til:</p><p>&nbsp;</p><p>Aktiekapital (nominelt):&nbsp; &nbsp; &nbsp; &nbsp;DKK 42.350.658,20</p><p>Antal stemmerettigheder:&nbsp;&nbsp;&nbsp; 211.753.291</p><p>&nbsp;</p><table class="prs-table"><tbody><tr><td><p><em>Yderligere information:</em></p><p>Peter Pudselykke, Head of Investor Relations</p><p>Gustav Høegh, Investor Relations Officer</p><p>Maribel Alonso Francisco, Communication Manager</p><p>&nbsp;</p><p>Telefon +45 3917 7300</p><p><a href="http://www.demant.com">www.demant.com</a></p></td></tr></tbody></table><h4>Kontakter</h4><ul>    <li>        Maribel Alonso Francisco, Communication Manager, +45 3171 9261, <a href="mailto:msbl@demant.com">msbl@demant.com</a>    </li></ul><h4>Om Demant A/S</h4><p>Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.</p><h4>Vedhæftninger</h4><ul>    <li>        <a href="https://via.ritzau.dk/ir-files/13560112/14866768/17592/2026-07%20Gennemf%C3%B8relse%20af%20kapitalneds%C3%A6ttelse.pdf">2026-07 Gennemførelse af kapitalnedsættelse.pdf</a>    </li></ul>

Demant A/S: Gennemførelse af kapitalnedsættelse

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

The DuPont formula helps understand the dynamics of value creation

Return on capital (ROE, ROI, ROIC, RONIC)

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up